Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones
|
Online news outlet Boardroom Media interviewed Starpharma CEO Dr Jackie Fairley following the release of its annual report and full-year results. In the interview, Dr Fairley shared the company’s latest DEP® trial results, as well as VivaGel® and upcoming milestones. |
To listen to the full interview, click here.
Starpharma sees positive results in ovarian cancer treatment
|
Online investor news outlet Finance News Network reported Starpharma’s positive results for its novel HER-2 targeted DEP® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla®, in a human ovarian cancer model. |
To watch the full news video, click here.
Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model
Starpharma today announced that treatment with a novel HER-2 Targeted DEP® conjugate from its internal Targeted DEP® program resulted in tumour regression and 100% survival in a preclinical human ovarian cancer model.
Promising efficacy signals for Starpharma’s DEP® trials
|
Biotech trade publication noted Starpharma announced promising efficacy signals in its ongoing clinical trials for both DEP® cabazitaxel and DEP® docetaxel. |
To read the full article, click here.
Annual report and full year financial results
Starpharma today released its annual report and financial results for the year ended 30 June 2019.
Promising efficacy signals observed in ongoing DEP® trials, including DEP® cabazitaxel escalation phase
Starpharma today announced that promising efficacy signals have been observed in its ongoing clinical trials for both DEP® cabazitaxel and DEP® docetaxel.
First Asian Regulatory Approvals Received for VivaGel® BV
Starpharma today announced that it has received the first regulatory approvals in South East Asia for VivaGel® BV. Mundipharma will be rolling-out the product in Asia under the brand name BETADINETM BV Gel.
Starpharma commences phase 1/2 DEP® irinotecan trial
Starpharma today announced that it has received the necessary regulatory and ethics approvals and will commence its phase 1/2 clinical trial for DEP® irinotecan. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® irinotecan to define a recommended phase 2 dose (RP2D), and to determine anti-tumour efficacy of the product in select tumour types. DEP® irinotecan is the third DEP® product to enter the clinic from Starpharma’s internal portfolio with a fourth, partnered DEP® candidate, AZD0466, also set to enter the clinic later this year.